Open AccessEvaluation of dexamethasone effects in COVID-19 treatment
Author(s) -
Hamza Khalifa Ibrahim,
Naeimah Ahmeed Ahseen,
Tousief Irshad Ahmed,
Nisreen Ahmeed Ahseen,
Noor-Alhooda Milood Al-Awkally,
Aejeeliyah Yousuf
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns1.4799
Subject(s) - dexamethasone , covid-19 , medicine , inflammation , pandemic , intensive care medicine , immunology , disease , virology , infectious disease (medical specialty) , outbreak
(COVID-19) Finding a cure for Corona virus sickness in 2019 will be a difficult task for researchers all over the globe, since it is associated with significant lung damage and the potential for multiple organ failure. To far, dexamethasone has shown substantial benefits in COVID-19, reducing mortality while improving recovery. There is a reduction in inflammation due to a reduction in inflammation-related immune responses and a decrease in cytokine production, which prevents COVID-19 from becoming more severe. Dexamethasone's significance in the treatment of COVID-19 is currently unproven. When it comes to combating this pandemic, COVID-19's pathophysiology and dexamethasone's efficacy are the deciding factors.